What Changed at MEDICAL IP

Every material change AI Health Index has tracked at MEDICAL IP: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Impact
Type
1 entry
Showing changes for MEDICAL IP only.Show the full log

August 2026

M
MEDICAL IP
Aug 10, 2026
MediumVerified
Clinical evidence

A retrospective study published in PLOS ONE validated MEDIP PRO's ability to segment orbital structures on CT imaging to assess Thyroid Eye Disease (TED) activity. The software was used to perform semi-automatic segmentation of extraocular muscles, intraorbital fat, and lacrimal glands. The resulting quantitative metrics successfully differentiated active from inactive TED, demonstrating an area under the curve (AUC) of 0.938 when combined with clinical parameters.

Our read

Published validation provides concrete evidence of the platform's segmentation accuracy and reliability for complex orbital anatomy. Health systems evaluating the solution can point to this study as proof of its capability to extract clinically meaningful, disease-specific biomarkers from routine imaging.

Related axis: Clinical and Operational EvidencePeer-reviewed publicationView source